|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2003-4-9
|
|
pubmed:abstractText |
The use of mature dendritic cells (DCs) presenting tumor-associated antigens (TAAs) to trigger tumor-specific T cells in vivo or in vitro represents a promising approach for cancer immunotherapy. We hypothesized that tumor antigens, mostly unidentified, are present on ovarian tumor cells and that mature DCs could be used to generate tumor-specific responses in unprimed patients. We also sought to measure preexisting antitumor immunity in patients with advanced ovarian cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/CD40 Ligand,
http://linkedlifedata.com/resource/pubmed/chemical/Cancer Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Carrier Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/RANK Ligand,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor Activator of Nuclear...,
http://linkedlifedata.com/resource/pubmed/chemical/TNFRSF11A protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/TNFSF11 protein, human
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:CarrollRichard GRG,
pubmed-author:ChoiYongwonY,
pubmed-author:ChuChristina SCS,
pubmed-author:CoukosGeorgeG,
pubmed-author:HudsonBrianB,
pubmed-author:JuneCarl HCH,
pubmed-author:KaiserLarry RLR,
pubmed-author:LevineBruce LBL,
pubmed-author:MausMarcela VMV,
pubmed-author:RileyJames LJL,
pubmed-author:RiversPatricia MPM,
pubmed-author:RubinStephen CSC,
pubmed-author:SchliengerKatiaK,
pubmed-author:TollAlanna JAJ,
pubmed-author:WooEdward YEY
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1517-27
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:12684428-Adult,
pubmed-meshheading:12684428-Aged,
pubmed-meshheading:12684428-Apoptosis,
pubmed-meshheading:12684428-CD40 Ligand,
pubmed-meshheading:12684428-Cancer Vaccines,
pubmed-meshheading:12684428-Carrier Proteins,
pubmed-meshheading:12684428-Cell Death,
pubmed-meshheading:12684428-Cell Line, Tumor,
pubmed-meshheading:12684428-Dendritic Cells,
pubmed-meshheading:12684428-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:12684428-Female,
pubmed-meshheading:12684428-Flow Cytometry,
pubmed-meshheading:12684428-Genes, MHC Class I,
pubmed-meshheading:12684428-Humans,
pubmed-meshheading:12684428-Immunotherapy,
pubmed-meshheading:12684428-Interferon-gamma,
pubmed-meshheading:12684428-Leukocytes, Mononuclear,
pubmed-meshheading:12684428-Male,
pubmed-meshheading:12684428-Membrane Glycoproteins,
pubmed-meshheading:12684428-Middle Aged,
pubmed-meshheading:12684428-Ovarian Neoplasms,
pubmed-meshheading:12684428-Phagocytosis,
pubmed-meshheading:12684428-Phenotype,
pubmed-meshheading:12684428-RANK Ligand,
pubmed-meshheading:12684428-Receptor Activator of Nuclear Factor-kappa B,
pubmed-meshheading:12684428-T-Lymphocytes,
pubmed-meshheading:12684428-Ultraviolet Rays
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients.
|
|
pubmed:affiliation |
Abramson Family Cancer Research Institute, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
